Earnings
Medicure Reports Financial Results for the Year Ended December 31, 2025 and Schedules April 27, 2026 Conference Call
Cash Burn Accelerates as Medicure Reports 7x Loss Widening Amid Pharmacy Expansion
Executive Summary
- Medicure Inc. reported annual net revenue of $28.9 million for FY 2025, up from $21.9 million in FY 2024.
- Net loss widened significantly to $7.1 million ($0.68 per share) compared to a $1.0 million loss in FY 2024.
- Revenue growth was driven by the Pharmacy Business Segment, which reached $20.3 million (up from $10.8 million), fueled by acquisitions of Gateway Medical Pharmacy and West Olympia Pharmacy.
- AGGRASTAT® sales declined to $5.7 million from $8.1 million due to generic competition.
- Adjusted EBITDA was negative $1.5 million, worsening from negative $437,000 in FY 2024.
- Unrestricted cash decreased to $3.8 million at December 31, 2025, down from $7.2 million the prior year.
- Key loss drivers included a $2.1 million CMS rebate liability and $2.6 million in non-cash amortization related to acquisitions.
- R&D investment remained steady at $3.2 million, funding Phase 3 trials for MC-1.
Material Impact
- The widening net loss from $1.0M to $7.1M is a significant deterioration of profitability, though the trend was visible in Q3 2025 results where losses also widened.
- Cash position has eroded by nearly half ($3.4 million decrease) over the year, leaving only $3.8 million on hand against an annualized loss rate that suggests immediate capital raising needs within 6 months.
- The pharmacy segment growth offsets pharma decline but introduces integration risks and higher cost of goods sold (COGS up 129% YoY in Q3).
- The CMS rebate liability is a one-time hit, but highlights regulatory pricing pressure on the core pharmaceutical business.
- Since the negative trend was established in the November 2025 earnings release, this FY announcement confirms known risks rather than introducing new surprises, categorizing it as Routine Negative rather than Material Shock.
MPH · Price
Company Overview
- Medicure Inc. operates a dual-segment business model combining pharmaceuticals and pharmacy services.
- Flagship Pharmaceutical Product: AGGRASTAT® (tirofiban) for acute coronary syndrome, facing generic competition.
- Secondary Pharma Product: ZYPITAMAG® (pyridoxamine), generating $6.5 million in FY 2025 revenue.
- Investigational Asset: MC-1 for PNPO deficiency, currently in Phase 3 trials.
- Pharmacy Segment: Includes Marley Drug and recently acquired Gateway Medical Pharmacy and West Olympia Pharmacy, now contributing the majority of revenue ($20.3M).
More from Medicure Inc.
May 21, 2026 · 17:00